UNSPSC 51281521: Pretomanid

Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.

UNSPSC 51281521 Pretomanid is a Commodity code for pharmaceutical products used in the treatment of drug-resistant tuberculosis, though recent state and local procurement activity under this code shows a significant mismatch. Seminole County, Florida posted an IFB in June 2026 classified under this code, but the actual scope of work — procurement of naloxone (an opioid-overdose reversal medication) and safe drug deactivation systems — falls entirely outside the pretomanid product line. State and local governments do not appear to be soliciting pretomanid through traditional competitive bidding at this time; the single recent opportunity tagged to this code represents pharmaceutical harm-reduction and community health support, not tuberculosis treatment.

The Seminole County opportunity, IFB 60459723LAS with a response deadline of July 26, 2023, sought annual delivery of 1,900 units of naloxone and 800 drug deactivation systems on a quarterly basis to the County Community Health Building in Sanford, Florida. The contract was structured as a two-year initial term with a one-year renewal option, fixed-fee pricing, and compliance requirements including E-Verify authorization, drug-free workplace certification, and federal compliance (Clean Air Act, Federal Water Pollution Control Act) tied to FEMA funding. This isolated solicitation does not establish a pattern of state and local activity under the pretomanid code; the tagging appears to reflect a data-classification error rather than active procurement demand for the product itself.